These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31352807)

  • 1. [De-escalation of antihyperglycemic treatment in patients with type 2 diabetes - when less is more].
    Jermendy G
    Orv Hetil; 2019 Aug; 160(31):1207-1215. PubMed ID: 31352807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study.
    Raebel MA; Ellis JL; Schroeder EB; Xu S; O'Connor PJ; Segal JB; Butler MG; Schmittdiel JA; Kirchner HL; Goodrich GK; Lawrence JM; Nichols GA; Newton KM; Pathak RD; Steiner JF
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):699-710. PubMed ID: 24639086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
    Gross JL; Kramer CK; Leitão CB; Hawkins N; Viana LV; Schaan BD; Pinto LC; Rodrigues TC; Azevedo MJ;
    Ann Intern Med; 2011 May; 154(10):672-9. PubMed ID: 21576535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Yurgin N; Secnik K; Lage MJ
    Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic response to newly initiated diabetes therapies.
    Karter AJ; Moffet HH; Liu J; Parker MM; Ahmed AT; Go AS; Selby JV
    Am J Manag Care; 2007 Nov; 13(11):598-606. PubMed ID: 17988185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
    BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment escalation from metformin monotherapy in youth-onset Type 2 diabetes mellitus: A retrospective cohort study.
    Vajravelu ME; Hitt TA; Amaral S; Levitt Katz LE; Lee JM; Kelly A
    Pediatr Diabetes; 2021 Sep; 22(6):861-871. PubMed ID: 33978986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin: an antihyperglycemic drug for non-insulin-dependent diabetes mellitus.
    Kupecz D
    Nurse Pract; 1995 Jul; 20(7):70-2. PubMed ID: 7675343
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
    Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.
    Cox SL
    Drugs Today (Barc); 2004 Jul; 40(7):633-43. PubMed ID: 15510236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.
    Abdelgani S; Puckett C; Adams J; Triplitt C; DeFronzo RA; Abdul-Ghani M
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3497-3504. PubMed ID: 34343296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.